Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA2DS2VASc scores: Experience from the Stockholm region

European Journal of Clinical Pharmacology

Volumn 70, Issue 12, 2014, Pages 1477-1485

  Forslund, Tomas ^a   Wettermark, Björn ^b   Wändell, Per ^b   Von Euler, Mia ^b   Hasselström, Jan ^b   Hjemdahl, Paul ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anticoagulant treatment; Aspirin; Atrial fibrillation; CHA2DS2VASc; Stroke; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN; ANTICOAGULANT AGENT;

AGED; ALCOHOLISM; AMBULATORY CARE; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COHORT ANALYSIS; DEATH; DEMENTIA; DIABETES MELLITUS; DRUG CONTRAINDICATION; FALLING; FEMALE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL HISTORY; MEDICAL SPECIALIST; POPULATION RESEARCH; PRESCRIPTION; PRIMARY MEDICAL CARE; RISK ASSESSMENT; SWEDEN; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE; VERY ELDERLY; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; HEMORRHAGE; RISK; STROKE;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; COHORT STUDIES; FEMALE; HEMORRHAGE; HUMANS; MALE; RISK; STROKE; SWEDEN; THROMBOEMBOLISM; WARFARIN;

EID: 84919911759     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1739-1     Document Type: Article

References (28)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P (2012) ESC Committee for Practice Guidelines (CPG); 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719-47
2. Forslund T, Wettermark B, Wandell P, von Euler M, Hasselstrom J, Hjemdahl P (2013) Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. Int J Cardiol 170:208-14
3. Friberg L, Rosenqvist M, Lip GY (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125:2298-307
4. Friberg L, Hammar N, Ring M, Pettersson H, Rosenqvist M (2006) Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Eur Heart J 27:1954-64
5. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patientswho have nonvalvular atrial fibrillation. Ann Intern Med 146:857-867
6. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. Europace. 2006;8:651-745.
7. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E (2007) BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370:493-503
8. Friberg L, Rosenqvist M, Lip GY (2012) Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 33:1500-10
9. Larsen TB, Lip GY, Skjøth F, Due KM, Overvad K, Hvilsted RL (2012) Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, And Health Cohort Study. Circ Cardiovasc Qual Outcomes 5:335-42
10. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C (2011) Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342:d124
11. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC Jr, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014 Apr 10. [Epub ahead of print]
12. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C (2011) Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 106:739-749
13. Coppens M, Eikelboom JW, Hart RG, Yusuf S, Lip GY, Dorian P, Shestakovska O, Connolly SJ (2013) The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J 34:170-6
14. Ludvigsson J, Otterblad-Olausson P, Pettersson BU, Ekbom A (2009) The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 24:659-667
15. Wändell P, Carlsson AC, Wettermark B, Lord G, Cars T, Ljunggren G (2013) Most common diseases diagnosed in primary care in Stockholm, Sweden 2011. Fam Pract 30:506-513
16. Zarrinkoub R, Wettermark B, Wändell P, Mejhert M, Ljunggren G, Kahan T (2013) The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail 15:995-1002
17. Carlsson AC, Wändell P, Ösby U, Zarrinkoub R, Wettermark B, Ljunggren G(2013) High prevalence of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden - a challenge for public health. BMC Public Health 13:670
18. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450
19. Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O (2010) Atrial fibrillation in the Malmo Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol 25:95-102
20. Nilsson AC, Spetz CL, Carsjo K, Nightingale R, Smedby B (1994) [Reliability of the hospital registry. The diagnostic data are better than their reputation; in Swedish]. Lakartidningen 91:598-605
21. Ingelsson E, Arnlov J, Sundstrom J, Lind L (2005) The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 7:787-791
22. Ragnarson Tennvall G, Apelqvist J, Eneroth M (2000) The inpatient care of patients with diabetes mellitus and foot ulcers. A validation study of the correspondence between medical records and the Swedish Inpatient Registry with the consequences for cost estimations. J Intern Med 248:397-405
23. Linnersjo A, Hammar N, Gustavsson A, Reuterwall C (2000) Recent time trends in acute myocardial infarction in Stockholm, Sweden. Int J Cardiol 76:17-21
24. Johansson LA, Westerling R (2000) Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics. Int J Epidemiol 29:495-502
25. Rosén M(2002) National Health Data Registers: a Nordic heritage to public health. Scand J Public Health 30:81-85
26. Wettermark B, Hammar N, Fored M, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M (2007) The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16:726-35
27. Sjalander S, Sjalander A, Svensson PJ, Friberg L (2014) Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace 16:631-8
28. Björck S, Palaszewski B, Friberg L, Bergfeldt L (2013) Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke 44:3103-8